The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Business
  • Tech
  • Bio
  • Companies
Thu, August 11, 2022 | 17:02
Manufacturing
Korea signs agreement with AstraZeneca for COVID vaccine
Posted : 2020-11-30 16:39
Updated : 2020-12-01 10:18
Print Preview
Font Size Up
Font Size Down
Vials labelled 'COVID-19 / Coronavirus vaccine / Injection only' and a syringe in front of an AstraZeneca logo in this Oct. 31 illustration / Reuters-Yonhap
Vials labelled "COVID-19 / Coronavirus vaccine / Injection only" and a syringe in front of an AstraZeneca logo in this Oct. 31 illustration / Reuters-Yonhap

By Kim Yoo-chul

The government has signed an agreement with AstraZeneca to secure 25 million doses of its COVID-19 vaccine, two sources directly involved with the matter said Monday. They said SK Bioscience would handle the manufacture of the vaccine, known as AZD1222, for domestic distribution.

According to the sources, the size of the deal is known to be "a few million dollars."

"The government agreed with AstraZeneca to secure a supply of its coronavirus vaccine," a government official said, asking not to be identified. "Other relevant details will be released within this week, at the earliest possible date."

Will AstraZeneca vaccine trial affect SK Bioscience IPO?
Will AstraZeneca vaccine trial affect SK Bioscience IPO?
2020-11-27 15:38  |  Health & Science

The official said the value of the deal would be equivalent to those the pharmaceutical company recently signed with Thailand and the Philippines.

Thailand signed a $200 million deal to procure 26 million doses of the AstraZeneca vaccine developed in collaboration with Oxford University. In the Philippines, more than 30 companies signed an agreement to buy at least 2.6 million doses from AstraZeneca, according to media reports. AstraZeneca was unavailable for comments.

Another government official said the government was in the "final stages" of fixing "some outstanding issues," such as guaranteed vaccine amount and total payment, as ruling and opposition lawmakers were negotiating on the amount of a third COVID-19 emergency relief funding package and what it should cover.

"The health ministry will take the central role ― government officials and health experts are on track to narrow their views over pricing and supply volume," the official said, adding that officials were working on how to prioritize vaccine recipients.

Prime Minister Chung Sye-kyun said Korea was in a "critical phase" after new daily COVID-19 infections soared above the 400 threshold. Chung told the public that the government would secure 30 million vaccine doses, although ruling party lawmakers are asking relevant agencies to secure more.

On a related note, AstraZeneca signed a deal with Korea's non-listed SK Bioscience to manufacture its vaccine products. The collaboration calls for the SK affiliate to manufacture AZD1222 for local and global markets.

The drug constituents are now being produced at SK's vaccine manufacturing facility in Andong, 270 kilometers southeast of Seoul with SK's local contractors handling international distribution, according to SK Bioscience.

AZD1222, the result of collaboration between Oxford University and AstraZeneca, is drawing attention around the world because it was the first vaccine material to be given permission to conduct Phase 3 clinical trials.



Emailyckim@koreatimes.co.kr Article ListMore articles by this reporter
 
LG
  • Korea urged to take preemptive steps to deal with climate change-induced disasters
  • What Seoul's worst rainfall in 115 years looked like
  • Musinsa's new store becomes hot spot in southern Seoul
  • Flood damage to vehicles during torrential rain to hit insurers
  • 'Children must play right now'
  • Bill Gates expected to meet with top business leaders in Korea
  • Seoul reiterates that '3 Nos' policy is not commitment to China
  • Han River sunset cruise: Seoul's new tourist focal point
  • [INTERVIEW] Polish arms deal may well lead to greater opportunities for Korea: expert
  • Samsung aims to attract more users with new foldable phones
  • Interactive News
  • With tough love,
  • 'Santa dogs' help rebuild burnt forests in Andong
  • 'Santa dogs' help rebuild burnt forests in Andong
  • A tale of natural wine
    • 'Good Doctor' director to debut Netflix's high-strung suspense series, 'A Model Family' 'Good Doctor' director to debut Netflix's high-strung suspense series, 'A Model Family'
    • Musical 'Kinky Boots' tells people to love themselves as they are Musical 'Kinky Boots' tells people to love themselves as they are
    • Death of young webtoon artist sparks controversy over harsh working conditions Death of young webtoon artist sparks controversy over harsh working conditions
    • Crime thriller 'Limit' is about mother's quest to save abducted son Crime thriller 'Limit' is about mother's quest to save abducted son
    • From P1Harmony to Zico, K-pop hotshots to perform in Abu Dhabi next month From P1Harmony to Zico, K-pop hotshots to perform in Abu Dhabi next month
    DARKROOM
    • Ice is melting, land is burning

      Ice is melting, land is burning

    • Tottenham 6-3 Team K League

      Tottenham 6-3 Team K League

    • Afghanistan earthquake killed more than 1,000

      Afghanistan earthquake killed more than 1,000

    • Divided America reacts to overturn of Roe vs. Wade

      Divided America reacts to overturn of Roe vs. Wade

    • Namaste: Yogis to celebrate International Yoga Day

      Namaste: Yogis to celebrate International Yoga Day

    The Korea Times
    CEO & Publisher : Oh Young-jin
    Digital News Email : webmaster@koreatimes.co.kr
    Tel : 02-724-2114
    Online newspaper registration No : 서울,아52844
    Date of registration : 2020.02.05
    Masthead : The Korea Times
    Copyright © koreatimes.co.kr. All rights reserved.
    • About Us
    • Introduction
    • History
    • Location
    • Media Kit
    • Contact Us
    • Products & Service
    • Subscribe
    • E-paper
    • Mobile Service
    • RSS Service
    • Content Sales
    • Policy
    • Privacy Statement
    • Terms of Service
    • 고충처리인
    • Youth Protection Policy
    • Code of Ethics
    • Copyright Policy
    • Family Site
    • Hankook Ilbo
    • Dongwha Group